Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. - Wikidata - awgldk - TriplyDB

Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.

Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.

http://www.wikidata.org/entity/Q37031949

about

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Bromodomain and Extra-terminal (BET) Protein Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth.Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance.Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.Targeting BET bromodomain proteins in solid tumors Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.AR Signaling in Breast Cancer.Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response.Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.BET bromodomain inhibitors synergize with ATR inhibitors in melanoma in melanoma Drugging Chromatin in Cancer: Recent Advances and Novel Approaches.Evolving molecular era of childhood medulloblastoma: time to revisit therapy.Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells.Targeting the Breast Cancer Kinome.Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue BET Bromodomain Proteins as Cancer Therapeutic Targets.Targeting Cancer Cells with BET Bromodomain Inhibitors.Non-kinase targets of protein kinase inhibitors.Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis BET inhibitors as novel therapeutic agents in breast cancer.Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics.The PI3K Pathway in Human Disease.Targeting bromodomain and extraterminal proteins in breast cancer.BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations.Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer.PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition.Landscaping a chromatin response to MEK inhibition.MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.CBT profiles of cabozantinib approved for advanced renal cell carcinomas.Probing the epigenome

P2860

Q33591876-BE99D15F-895D-4DDF-8373-D0DB2073DC69 Q36185007-C9118A01-7919-4567-A09D-F6B5875DAA0F Q36496096-FEFE08BE-0563-4586-A801-A24FA65F6213 Q36956610-C5B479F6-3DAA-47C2-9990-1BA1A42D9C5A Q37295285-C5DA8F7F-4A10-41E7-A7C9-3A8E79B30EC4 Q37330876-47363573-B957-42AC-B5D6-E2A300081ACF Q37333948-C1C71278-C00D-40AD-AF9C-2DDF12BC2CAB Q37619860-D752A74F-0BB5-4B2F-BE2D-69BCA6189778 Q37718224-D2E13721-02A8-4828-A481-583CA17F8EB6 Q37721492-A4F44565-11BA-46A5-89E5-F88BAFE692A9 Q38605020-E5147472-6861-432F-9CBE-14B473C5F64A Q38626078-8D963704-F8AC-4884-BE11-B22AA96800C9 Q38630705-28A43A64-A1D1-4110-9E02-37EBE5240A16 Q38641649-1A6E3E72-1074-43A3-9FF1-17DCA7D038E8 Q38652681-2F1FBDCC-8A98-4743-BE7F-FC00C70B95FD Q38734040-F870C0F6-436F-491D-8DBF-73D1ACB3C294 Q38743421-AE2C85E3-EE24-4E5B-9265-DDB3C611A4C3 Q38744664-9F968675-24FD-4796-8F7E-BFF9B674EB3A Q38764654-C4B01CD2-1F00-4603-8B1C-7B728F7941E1 Q38799987-8808AA82-784A-4A7D-B016-393872773910 Q38836110-2E7A4E8E-22EB-4E23-A252-34B93CF774F6 Q38850598-593D1ABB-2192-4EE9-822C-16937D4AF560 Q39071349-CA0E30C6-523C-40D5-A5DA-B65EA1955580 Q39141456-0F52D8F4-A30D-402A-872B-174829E65024 Q39171961-BA035948-95D5-4014-94B9-B99E0CC28E7B Q41592643-6E722332-5124-45A8-B1B1-A7262DC7FDA4 Q42320410-79FCAA74-F016-462C-A09C-E250F745F154 Q42378528-EC280242-5637-4946-90A6-271441572D31 Q42382162-5476AFAD-6C38-41BA-BD9D-20BE3149FF04 Q42694831-A237F560-EA94-4F18-8FC0-D3D9D796BC24 Q44988870-5E99DBB4-FA17-4FA1-9943-335E171B431F Q46546002-AB2116E4-02FD-4C4C-BF45-CE789E679002 Q47385983-53A9EE21-38BE-43B9-AC49-14BE69AF7C82 Q47651456-3438C404-445F-4B45-9799-0D8261A6CD0F Q50056092-655C586E-023D-454C-9E69-5D90D089F0E6 Q51114244-05C7E858-49CF-41B1-84C4-91FDA36A1031 Q52782454-98D24A15-DB15-40CE-8B44-7892977C7E69 Q53693522-7E12AF9E-3711-4311-A46E-3C08ED7495BB Q53782217-AA9BC2A2-4774-493D-B6DC-65DC70AD7CAE Q54932267-88C08BAE-6833-4FB7-9CE2-E68E4ADEC01B

P2860

Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.

http://www.wikidata.org/entity/Q37031949

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Kinase and BET Inhibitors Toge ...... vercome Resistance to Therapy.

@en

Kinase and BET Inhibitors Toge ...... vercome Resistance to Therapy.

@nl

type

label

Kinase and BET Inhibitors Toge ...... vercome Resistance to Therapy.

@en

Kinase and BET Inhibitors Toge ...... vercome Resistance to Therapy.

@nl

prefLabel

Kinase and BET Inhibitors Toge ...... vercome Resistance to Therapy.

@en

Kinase and BET Inhibitors Toge ...... vercome Resistance to Therapy.

@nl

P1433

Q37031949-1D28D7B8-0CC4-44C9-96BA-D3378BAAC874

P1476

Q37031949-A890D5FC-70F6-4957-8390-31A637977BA9

P2093

Q37031949-5AB59968-960A-46AE-8064-4D33485FAA1B

Q37031949-73014485-A385-4DFA-BF99-C690481AEE1A

Q37031949-BF2F60C2-9C65-4C22-99C7-1AFC5659AD1E

Q37031949-ED18B2A8-CCDD-427B-81FC-9B12818787FB

Q37031949-ED3381F0-8CBE-4E03-98C6-C9529BD763F8

Q37031949-F1C8545B-BF51-45FE-BD91-DC15C2E13E02

Q37031949-FCF9FA96-219A-4AF4-90E3-B178701BD546

P2860

Q37031949-02046310-6B01-44FC-B51C-C3A0941B398A

Q37031949-09A3BCC6-8606-43C3-99F9-D37CBADE0736

Q37031949-10B23463-82C1-47DB-87E4-0D00E8D87B7E

Q37031949-129694E8-215D-4517-9861-1B229717A0BB

Q37031949-1315DE5A-77BF-462B-96B7-0D8D72D310F5

Q37031949-1A0614B1-34D8-4708-A058-E9624B047AE7

Q37031949-244121B6-C68C-4403-A161-6959A443DABE

Q37031949-2B209C21-FA2F-47A7-AE95-E9B81E68F640

Q37031949-2D1FD08D-BB13-4962-963B-18F2711168BC

Q37031949-3499614D-EF78-43C7-BEE8-BF4EC937A3C9

P304

Q37031949-19DF3FB8-6BC2-45A6-817C-9179B1ED97A5

P31

Q37031949-DC1A49F2-B3DD-4EBF-8417-290EB2A5E396

P356

Q37031949-FFA90E98-9E64-46D3-8E8F-1803DAD52369

P433

Q37031949-59EA15D1-0F22-4CEF-943A-128A2CCE1BCC

P478

Q37031949-DE02685C-9795-4D08-B438-383774ABF174

P577

Q37031949-ECF11654-1205-4583-9E20-09320B499614

P5875

Q37031949-7ABFBB8D-3921-4937-84D9-51B74312993B

P698

Q37031949-9B460028-F137-43C5-B14F-52DDBF84FC2B

P932

Q37031949-7476CE40-1C91-4C60-B2BE-5F8A5859F9E0

P356

J.CCELL.2015.05.006

P1433

P1476

Kinase and BET Inhibitors Toge ...... vercome Resistance to Therapy.

@en

P2093

Alan J Khaykin

http://www.w3.org/2001/XMLSchema#string

Celine Lefebvre

http://www.w3.org/2001/XMLSchema#string

Elias E Stratikopoulos

http://www.w3.org/2001/XMLSchema#string

Matthias Szabolcs

http://www.w3.org/2001/XMLSchema#string

Meaghan Dendy

http://www.w3.org/2001/XMLSchema#string

Ming-Ming Zhou

http://www.w3.org/2001/XMLSchema#string

Ramon Parsons

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of BET bromodomains

Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release

Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition

Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

c-Myc regulates transcriptional pause release

AKT/PKB signaling: navigating downstream

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

P304

837-851

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCELL.2015.05.006

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278045918

http://www.w3.org/2001/XMLSchema#string

P698

26058079

http://www.w3.org/2001/XMLSchema#string

P932

4918409

http://www.w3.org/2001/XMLSchema#string